Screener
Halozyme Therapeutics HALO Goodwill
Goodwill at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total current assets | 933,024 | 825,207 |
| Property and equipment, net | 84,271 | 82,137 |
| Prepaid expenses and other assets | 55,090 | 53,551 |
| Goodwill | 581,732 | 580,360 |
| Intangible assets, net | 922,443 | 981,467 |
| Restricted cash | 848 | 2,601 |
| Total assets | $2,577,408 | $2,525,323 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's goodwill?
- Halozyme Therapeutics (HALO) reported goodwill of $581.73M in Q2 2026.
- How has Halozyme Therapeutics's goodwill changed year-over-year?
- Halozyme Therapeutics's goodwill increased by 39.6% year-over-year, from $416.82M to $581.73M.
- What does goodwill mean?
- The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.
Ask your AI about Halozyme Therapeutics's goodwill.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude